Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Ongoing Brand or Portfolio Management

Sponsored by

Finalist

Revlimid

Celgene


Summary of work

Following NICE’s approval of Revlimid, for multiple myeloma (MM) in early 2009, we at Celgene set out to achieve not only increased access to the treatment, but also a whole new understanding of the disease itself. 

A full paradigm shift was required, from MM as an end-of-life condition, with a short-term approach and ‘treatment-free’ phases as the goal, to new understanding of it as a ‘chronic condition’ requiring continuous treatment – an entirely new concept for the medical profession and patients alike. 

Thus we worked tirelessly to educate the relevant communities on this new approach, to increase access while emphasising the importance of treatment duration to help drive overall survival – in which we now lead Europe, despite our third line (versus their second line) positioning. 

All the time, we demonstrated the value, efficacy and cost effectiveness of the treatment, even putting our money where our mouth is and offering Revlimid free of charge, after 26 cycles, through a pioneering Patient Access Scheme which is delivering exactly what we told NICE it would. 

As the first and only of its kind, the scheme and other learnings from the UK Revlimid approach are being viewed as best practice across Celgene Europe and by the UK oncology community.

 

 

Executive summary as submitted


COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...